Search clinical trials for: lapatinib

Total 1444 results

Tianjin Medical University Cancer Institute and...

Unknown

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

Gastric Carcinoma
Xinqiao Hospital of Chongqing

Withdrawn

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

Advanced Non-squamous Non-small-cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Unknown

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Recurrent and Metastatic Gastric Cancer

China
Sir Run Run Shaw Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

Metastatic Gastric Adenocarcinoma

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

Lung Adenocarcinoma

China
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Breast Cancer

United States, Peru, Argentina, Mexico
Bristol-Myers Squibb

Terminated

Study of Dasatinib in Patients With Advanced Solid Tumors

Tumors

United States
AIPING ZHOU

Recruiting

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Esophagus Squamous Cell Carcinoma

China
Biogen

Completed

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Myeloid Leukemia | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome | Lymphoid Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
Julie E. Bauman, MD, MPH
Bristol-Myers Squibb

Terminated

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Squamous Cell Carcinoma Of The Head And Neck

United States
Nanfang Hospital of Southern Medical University

Unknown

Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Leukemia, Lymphoblastic, Acute

China
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
SCRI Development Innovations, LLC
Bayer; Boehringer Ingelheim; Exelixis; Foundation Medicine

Completed

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Non-small Cell Lung Carcinoma | Urothelial Carcinoma | Gastrointestinal Carcinoma, Non-colon | Upper Aerodigestive Tract Carcinoma

United States
Intergroupe Francophone de Cancerologie Thoracique

Completed

Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (ACE-Lung)

Non Small Cell Lung Cancer

France
The Netherlands Cancer Institute
Boehringer Ingelheim; Merck Serono International SA

Completed

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer (AFACET)

Carcinoma, Non-Small-Cell Lung

Netherlands
Boehringer Ingelheim

Completed

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Neoplasms

France
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male Volunteers

Healthy
Jorge J. Castillo, MD
Bristol-Myers Squibb

Terminated

Dasatinib In Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia | DASATINIB

United States
Bristol-Myers Squibb

Completed

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Leukemia, Myeloid, Chronic-Phase (CML-CP)
Versailles Hospital
University Hospital, Bordeaux; Maisonneuve-Rosemont Hospital

Completed

OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) (OPTIM-DASA)

Chronic Myelogenous Leukemia, BCR/ABL Positive

France, Canada
University of California, San Diego
Pfizer

Completed

Ramipril for the Treatment of COVID-19 (RAMIC)

COVID-19

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Withdrawn

A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib

Esophageal Neoplasms
Hebei Medical University Fourth Hospital

Enrolling by invitation

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Breast Cancer

China
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

Chronic Hepatitis C

Australia, France, United Kingdom, Spain, Russian Federation, Brazil, Poland, Sweden
China Medical University Hospital

Terminated

ErbB2 Positive Metastatic Breast Cancer

Metastatic Breast Cancer

Taiwan
Global Isotopes, LLC d/b/a Zevacor Molecular

Completed

Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

Metastatic Prostate Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Breast Cancer

China
Case Comprehensive Cancer Center
National Cancer Institute (NCI); United States Department of Defense

Completed

Chemotherapeutic Agents in Brain/Breast

Breast Cancer | Metastatic Cancer

United States
Merck Sharp & Dohme LLC

Completed

Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)

Neoplasms | Nausea | Vomiting
University of Copenhagen
Copenhagen University Hospital, Hvidovre

Recruiting

Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.

Obesity

Denmark
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
Bristol-Myers Squibb
PPD; ICON Clinical Research; Q2 Solutions; Molecular MD; MultiPharma; Steering Committee and other collaborators

Completed

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

Chronic Phase Chronic Myeloid Leukemia

Italy, Thailand, United States, Belgium, Czechia, Hungary, Argentina, Austria, Brazil, Canada, China, France, Korea, Republic of, Poland, Spain
Bristol-Myers Squibb

Completed

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

Advanced Breast Cancer

United States, Spain, Italy
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Spain, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Puerto Rico, Singapore, South Africa, Taiwan, United Kingdom, Australia, France, Philippines, Sweden, Thailand, Russian Federation, China, Poland, Finland, Isra... and more
Boehringer Ingelheim

Completed

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Neoplasms

United States
Bristol-Myers Squibb
Innovative Therapies For Children with Cancer Consortium

Completed

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

Leukemia

Germany, United Kingdom, France, Austria, Italy, Netherlands
National Research Center for Hematology, Russia

Active, not recruiting

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (READIT)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | BCR-ABL Positive Chronic Myelogenous Leukemia

Russian Federation
Norwegian University of Science and Technology

Completed

Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (NordCML006)

Chronic Myeloid Leukemia

Sweden, Finland, Norway
Elevar Therapeutics

Terminated

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Tianjin Medical University Cancer Institute and...

Recruiting

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Gastric Cancer

China
Sun Yat-sen University

Unknown

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC (APPEAL)

Lung Cancer

China
Hospital Universitario Dr. Jose E. Gonzalez
Fernando De la Garza Salazar

Recruiting

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, Chronic Phase

Mexico
Giselle Sholler
Beat NB Cancer Foundation; K C Pharmaceuticals Inc.; Team Parker for Life; Dell...

Recruiting

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)

Neuroblastoma

United States, Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Sarcoma | Lymphoma | Kidney Cancer | Unspecified Childhood Solid Tumor, Protocol Specific | Testicular Germ Cell Tumor | Ovarian Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Liver Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

United States
Wei Zhao
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Hematological Neoplasms

China
University of Southern California
National Cancer Institute (NCI)

Unknown

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Liver Metastases | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States

Search clinical trials for: lapatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations